QLM3003 vs ZL-82

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK · full Atopic Dermatitis pipeline

QLM3003

Developed by Qilu Pharmaceutical

Phase 3 in Atopic Dermatitissmall molecule
Partial signal

NCT06058000 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and enrolled 120 participants, with a clinical disease-activity endpoint (EASI-75). However, no primary endpoint results or statistical comparison are available, so the trial provides well-designed but currently incomplete evidence.

Next expected readout: March 2027 · NCT06880276 (registry estimate)

No aligned efficacy figure on record for this race.

ZL-82

Developed by Chengdu Zenitar Biomedical Technology

Phase 2 in Atopic DermatitisSmall molecule (oral JAK3 inhibitor)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07193589 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointQLM3003ZL-82
EASI-75—Trial running · NCT06880276—Not reported
IGA 0/1 with 2-point improvement—Trial running · NCT06880276—Not reported
EASI-90—Trial running · NCT06880276—Not reported
EASI, % change—Trial running · NCT06880276—Not reported

EASI-75

QLM3003
—Trial running · NCT06880276
ZL-82
—Not reported

IGA 0/1 with 2-point improvement

QLM3003
—Trial running · NCT06880276
ZL-82
—Not reported

EASI-90

QLM3003
—Trial running · NCT06880276
ZL-82
—Not reported

EASI, % change

QLM3003
—Trial running · NCT06880276
ZL-82
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

QLM3003: no structured comparison results are available for Atopic Dermatitis.

ZL-82: no structured comparison results are available for Atopic Dermatitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: QLM3003's landscape · ZL-82's landscape